It's a wrap!
Goodbye 2022!
Looking back at 2022, we are grateful for another challenging, yet incredible year alongside customers, collaborators, and the whole bioprinting community.
Here is a round up of your favorite resources and key milestones of 2022 that have brought us one step closer to reducing our dependence on animal testing and creating a sustainable future of health.
Updates to existing portfolio
BIO X Series Gen 3 and DNA Studio 4
With refined manufacturing processes, rigorous quality control and powered by DNA Studio 4, the bioprinters that disrupted the industry are reloaded and ready to do it again.
Explore all amazing new features of DNA Studio 4, that help you simplify, explore, expedite and do even more with your 3D bioprinter.
In the spotlight: Customers share their success
Application Notes
Most Downloaded throughout 2022
Key milestones and other highlights
BBC Click visits CELLINK
Take a tour of the CELLINK lab with Shiona McCallum, host of BBC’s Click and our CSO, Itedale Namro Redwan, and listen as they discuss how 3D bioprinting is advancing research today. Plus, hear from Prof. Simonsson to learn how her team is working on printing cartilage for patients with muscular issues.
Inauguration of GMP lab to enable clinical grade bioinks for human applications
The GMP facility will provide world class bioinks for pharmaceutical, medical researchers and manufacturers that want to comply with FDA and EU quality and safety regulations.
Centre of Excellence Established in India
CELLINK and the Indian Institute of Science (IISc) have opened the doors to the first 3D bioprinting Centre of Excellence, which will focus on providing researchers tools to advance discoveries in tissue engineering, regenerative medicine and drug discovery.
Uppsala University sends 3D bioprinted constructs to space
CELLINK is collaborating with prof. Kozlova’s group at Uppsala University and the Swedish Space Corporation amongst others to study the beneficial effect of microgravity on the production of insulin.
CELLINK is awarded Göteborgs Companipris
After being awarded Göteborgs Companipris in 2020 for the impact we’re having on the life science industry, we were humbled and honored to be one of three companies to accept the award on stage in 2022.
CELLINK entered collaboration agreement with Spermosens AB, Malmö University and SLU
Our collaboration is part of the research call Prospekt 21 and seeks to develop an in vitro diagnostic (IVD) device that helps determine infertility.
CELLINK enters collaboration with Zoan BioMed to Develop Bioinks for Bone Regeneration and Coral Restoration
During the collaboration, CELLINK will provide expertise on bioink development while Zoan BioMed will contribute with in-depth knowledge about coral growth characteristics.
